Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institution

BACKGROUND: Only 15–20% of pancreatic ductal adenocarcinoma (PDAC) patients are upfront surgical candidates at presentation, and for this cohort of patients, the 5-year survival is a mere 20% despite adjuvant therapy. Previous data indicate that in clinical practice most of these cases are “borderli...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Pancreat Cancer
Main Authors: Recio-Boiles, Alejandro, Vondrak, Jessica, Veeravelli, Summana, Mancuso, James J., Saboda, Kathylynn, Roe, Denise J., Riaz, Irbaz Bin, Scott, Aaron J., Elquza, Emad, McBride, Ali, Babiker, Hani M.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170377/
https://ncbi.nlm.nih.gov/pubmed/32313882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/apc.2020.02.01
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares